The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. While it ...

GSK plc (NYSE:GSK) develops and markets a wide range of healthcare products, including vaccines, specialty medicines, and ...

when the companies agreed to collaborate on marketing future and current products. In 2013, GSK divested its thrombosis portfolio to Aspen, but retained ownership in China, Hong Kong, Macau ...

Formerly known as GlaxoSmithKline ... It is also expanding its antibiotics and vaccines portfolio. Some of its significant products include Gepotidacin, the first completely new antibiotic ...

Bringing people together is the best way to innovate and deliver products that transform ... the vaccines of the future. GSK’s broad and far-reaching vaccine portfolio. GSK’s marketed vaccines ...

The company’s oncology portfolio, which had been facing ... or under regulatory review. This year, GSK expects to launch five new products/line extensions, including Blenrep (relaunch in ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

("GSK" or the "Company") (NYSE ... Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings.